Evidence map›Paper›PMID 40481578›Full record

ArticlePediatric rheumatology online journal2025

Juvenile localized scleroderma: a large retrospective cohort study from a tertiary care center.

Bugra Han Egeli, Johnathan Dallas, Diana B Reusch, Katharina S Shaw, Stephen Gellis, Robert Sundel, Mary Beth Son, Ruth Ann Vleugels, Fatma Dedeoglu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric rheumatology online journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Bugra Han EgeliDivision of Immunology, Rheumatology Program, Boston Children's Hospital, 300 Longwood Avenue, 02115, Boston, MA, USA.
Johnathan DallasWestern Atlantic University School of Medicine, Freeport, Grand Bahama, Bahamas.
Diana B ReuschDepartment Dermatology & Department of Pediatrics, University of Massachusetts, Amherst, MA, USA.
Katharina S ShawInstructor of Dermatology, Perelman School of Medicine, University of Pennsylvania, Pennsylvania, USA.
Stephen GellisDivision of Immunology, Dermatology Program, Boston Children's Hospital, Boston, MA, USA.
Robert SundelDivision of Immunology, Rheumatology Program, Boston Children's Hospital, 300 Longwood Avenue, 02115, Boston, MA, USA.
Mary Beth SonDivision of Immunology, Rheumatology Program, Boston Children's Hospital, 300 Longwood Avenue, 02115, Boston, MA, USA.
Ruth Ann VleugelsDivision of Immunology, Dermatology Program, Boston Children's Hospital, Boston, MA, USA.
Fatma DedeogluDivision of Immunology, Rheumatology Program, Boston Children's Hospital, 300 Longwood Avenue, 02115, Boston, MA, USA. fatma.dedeoglu@childrens.harvard.edu.ORCID http://orcid.org/0000-0002-7516-0848

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundJuvenile localized scleroderma is a rare pediatric inflammatory disease that primarily affects the skin and subcutaneous tissue but also has the potential to impact deeper tissues and can be associated with extracutaneous manifestations, leading to substantial impairment and disability. Management approaches vary, but in recent years, expert groups have attempted to streamline the approach to care with consensus treatment plans.

methodsThis retrospective cohort study included pediatric juvenile localized scleroderma patients with ≥ 3 years of follow-up identified within a 21-year period (1999-2020) at a single tertiary care pediatric hospital in the USA. Data on demographics, disease characteristics, and treatment trends were analyzed, with a focus on systemic versus topical therapy and treatment trends before and after the publication of the Childhood Arthritis and Rheumatology Research Alliance juvenile localized scleroderma consensus treatment plan in 2012.

resultsA total of 101 juvenile localized scleroderma patients fulfilled our inclusion criteria. Sixty-three patients were treated with systemic therapy, and 38 were treated with topical therapy. Patients on systemic therapy were more commonly treated in a combined rheumatology-dermatology program (67%) or rheumatology clinic (30%), whereas those on topical therapy were primarily treated in a dermatology clinic (71%). Starting in 2013, a significantly greater percentage of all patients were treated in the combined program (47% vs. 20%, p = 0.008), and a significantly greater percentage of patients received systemic therapy (78% vs. 55%, p < 0.05).

conclusionThis juvenile localized scleroderma cohort is one of the largest reported from a single center and demonstrated an increase in the use of systemic therapy following the publication of the Childhood Arthritis and Rheumatology Research Alliance juvenile localized scleroderma consensus treatment plan in 2012. Further studies on long-term treatment outcomes and therapeutic approaches utilized when first-line treatment failures occur are warranted.

Indexed as

Scleroderma, LocalizedAdolescentChildChild, PreschoolCohort StudiesFemaleHumansMaleRetrospective StudiesTertiary Care CentersConsensus treatment plansDermatologyJuvenile localized sclerodermaRheumatologyRheumatology dermatologySclerodermaTreatment

Identifiers

PMID40481578
PMCPMC12142819

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.